Regorafenib Hydrochloride
Regorafenib Hydrochloride (BAY73-4506 hydrochloride) is an orally bioavailable, small-molecule multikinase inhibitor targeting key angiogenic, stromal, and oncogenic receptor tyrosine kinases. It demonstrates potent antitumor activity in preclinical models, supporting its research use in oncology for both in vitro mechanistic studies and in vivo efficacy experiments.
Product Specifications
CAS Number
835621-07-3
Product Name Alternative
CRET, BAY73-4506 Hydrochloride, BAY73-4506 hydrochloride, Autophagy, BAY 73-4506, inhibit, Platelet-derived growth factor receptor, PDGFR, Inhibitor, RET, Regorafenib, Regorafenib Hydrochloride, Raf-1, Raf kinases, Raf, VEGFR, Vascular endothelial growth factor receptor
Field of Research
Cardiovascular Research, Cell Biology, Pharmacology & Drug Discovery, Signal Transduction
Purity
99.56% (May vary between batches)
Solubility
DMSO:40 mg/mL (77.03 mM)
Smiles
Cl.CNC (=O) c1cc (Oc2ccc (NC (=O) Nc3ccc (Cl) c (c3) C (F) (F) F) c (F) c2) ccn1
Molecular Formula
C21H16Cl2F4N4O3
Molecular Weight
519.28
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
ED0493Hu 96 Well
Human anti-Bullous Pemphigoid 180 antibody, BP180-Ab ELISA KIT
Sign In for Pricing
View Details 
